TS01.02 Novel Anti–CTLA-4 Antibody Quavonlimab Plus Pembrolizumab as First-Line Therapy for NSCLC: Extended Follow-up From a Phase 1 Study by Cho, B.C., Perets, R., Rasco, D.W., Ahn, M.-J., Spigel, D.R., Yoh, K., Kim, D.-W., Gutierrez, M., Lee, D.H., Nagrial, A., Satouchi, M., Kotasek, D., Maurice-Dror, C., Niu, J., Rajasagi, M., Siddiqi, S., Li, Xiaoyun (Nicole), Cyrus, J., Altura, R.A., Bar, J.

Get full text